See more : Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Income Statement Analysis – Financial Results
Complete financial analysis of iXensor Co., Ltd. (6734.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iXensor Co., Ltd., a leading company in the Healthcare industry within the Healthcare sector.
- Von Roll Holding AG (0QPV.L) Income Statement Analysis – Financial Results
- Sea & Land Integrated Corp. (5603.TWO) Income Statement Analysis – Financial Results
- Aldel Financial II Inc. Units (ALDFU) Income Statement Analysis – Financial Results
- Nicolet Bankshares, Inc. (NIC) Income Statement Analysis – Financial Results
- Delta Apparel, Inc. (DLA) Income Statement Analysis – Financial Results
iXensor Co., Ltd. (6734.TWO)
About iXensor Co., Ltd.
iXensor Co., Ltd. provides technology platform that turns smartphones into in vitro diagnostic devices through its smart color sensing technology for connected healthcare. The company's PixoTest technology uses the lighting and image sensing module of the smartphone to detect the color change reaction on the immunoassay or colorimetric strip. It offers PixoTest Blood Glucose Monitoring System and PixoTest POCT System for chronic diseases management; Eveline Smart Fertility System and Eveline Care Telehealth Platform for women's health management; and PixoTest COVID-19 Rapid Antigen Test for infectious disease management, as well as PixoHealth Pass Admin app and Web portal. The company was founded in 2012 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 20.89M | 105.24M | 24.79M | 15.92M | 30.03M |
| Cost of Revenue | 19.29M | 42.63M | 20.17M | 11.42M | 21.00M |
| Gross Profit | 1.60M | 62.60M | 4.62M | 4.50M | 9.03M |
| Gross Profit Ratio | 7.65% | 59.49% | 18.63% | 28.28% | 30.06% |
| Research & Development | 26.24M | 28.04M | 47.08M | 36.05M | 42.35M |
| General & Administrative | 19.35M | 17.61M | 19.29M | 24.29M | 41.08M |
| Selling & Marketing | 19.04M | 22.19M | 19.78M | 22.98M | 34.32M |
| SG&A | 38.39M | 39.79M | 39.07M | 47.27M | 75.72M |
| Other Expenses | 0.00 | 421.00K | 8.38M | 3.30M | 0.00 |
| Operating Expenses | 64.64M | 67.84M | 86.15M | 83.32M | 114.41M |
| Cost & Expenses | 83.93M | 110.47M | 106.32M | 94.74M | 135.41M |
| Interest Income | 160.00K | 69.00K | 64.00K | 240.00K | 904.00K |
| Interest Expense | 492.00K | 150.00K | 48.00K | 127.00K | 177.00K |
| Depreciation & Amortization | 5.95M | 7.13M | 8.70M | 10.88M | 7.80M |
| EBITDA | -56.76M | 2.39M | -64.33M | -65.60M | -92.59M |
| EBITDA Ratio | -271.70% | 2.27% | -259.64% | -404.36% | -337.11% |
| Operating Income | -63.04M | -4.74M | -73.08M | -75.27M | -109.04M |
| Operating Income Ratio | -301.77% | -4.51% | -294.74% | -472.71% | -363.07% |
| Total Other Income/Expenses | -156.00K | 340.00K | 8.40M | 3.41M | 4.38M |
| Income Before Tax | -63.19M | -4.89M | -73.08M | -76.61M | -104.65M |
| Income Before Tax Ratio | -302.51% | -4.65% | -294.75% | -481.12% | -348.47% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -63.19M | -4.89M | -73.08M | -76.61M | -104.65M |
| Net Income Ratio | -302.51% | -4.65% | -294.75% | -481.12% | -348.47% |
| EPS | -2.88 | -0.09 | -1.40 | -1.55 | -2.15 |
| EPS Diluted | -2.88 | -0.09 | -1.40 | -1.55 | -2.15 |
| Weighted Avg Shares Out | 21.94M | 54.19M | 52.28M | 49.28M | 48.68M |
| Weighted Avg Shares Out (Dil) | 21.94M | 54.19M | 52.28M | 49.28M | 48.68M |
Source: https://incomestatements.info
Category: Stock Reports